Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease
Recruiting
Observational Study
Focal Segmental Glomerulosclerosis
Minimal Change Disease
FSGS
MCD
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Sex
- Any
- Study type
- Observational
- Participants needed
- 300 (estimated)
- Sponsor
- University of Michigan · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The morbidity of recurrence of focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) after transplant is well-recognized and include contemporary reduction in quality of life, edema, early graft loss and mortality. Efforts to understand its mechanisms and improve its treatment have been limited by small sample sizes in single center studies and misclassification in registry st…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Retrospective non-consented participant group had a transplant from the year 2000 and onward.
* Diagnosis of FSGS or MCD in the native kidney (prior to transplant).
Exclusion Criteria:
* Pathologic diagnosis other than FSGS or MCD
* FSGS or MCD secondary to a known disorder …
Contacts